Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial

The Lancet Oncology

Volumn 15, Issue 2, 2014, Pages 213-222

  Wu, Yi Long ^a   Zhou, Caicun ^b   Hu, Cheng Ping ^c   Feng, Jifeng ^d   Lu, Shun ^e   Huang, Yunchao ^f   Li, Wei ^g   Hou, Mei ^h   Shi, Jian Hua ⁱ   Lee, Kye Young ^j   Xu, Chong Rui ^a   Massey, Dan ^k   Kim, Miyoung ^l   Shi, Yang ^m   Geater, Sarayut L ⁿ  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SHANGHAI PULMONARY HOSPITAL   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d Jiangsu Provincial Tumor Hospital   (China)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f KUNMING MEDICAL UNIVERSITY   (China)

^g THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^h SICHUAN UNIVERSITY   (China)

ⁱ LINYI CANCER HOSPITAL   (China)

^j Konkuk University Hospital   (South Korea)

^k BOEHRINGER INGELHEIM LTD   (United Kingdom)

^l Boehringer Ingelheim Korea   (South Korea)

^m Boehringer Ingelheim Shanghai Pharmaceuticals Co Ltd   (China)

ⁿ PRINCE OF SONGKLA UNIVERSITY   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE;

ABNORMAL LABORATORY RESULT; ACNE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARM PAIN; ARTICLE; ASIAN; BONE MARROW DEPRESSION; CANCER STAGING; CHINA; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE; GENE DELETION; GENE MUTATION; HEMOPTYSIS; HUMAN; HUMAN TISSUE; HYPOKALEMIA; HYPONATREMIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LOSS OF APPETITE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PAIN; PARONYCHIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SHOULDER PAIN; SOUTH KOREA; STOMATITIS; SURVIVAL TIME; THAILAND; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEAKNESS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPUBLIC OF KOREA; RISK FACTORS; THAILAND; TIME FACTORS; TREATMENT OUTCOME;

EID: 84892997539     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70604-1     Document Type: Article

References (29)

1. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
2. Azzoli CG, Temin S, Aliff T, et al. 2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011, 29:3825-3831.
3. Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl 7):VII56-VII64.
4. Buettner R, Wolf J, Thomas RK Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013, 31:1858-1865.
5. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
6. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
7. Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343:342-350.
8. Wind S, Schmid M, Erhardt J, Goeldner RG, Stopfer P Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. Clin Pharmacokinet 2013, 52:1101-1109.
9. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997, 57:4838-4848.
10. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
11. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
12. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
13. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
14. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
15. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
16. Sekine I, Yamamoto N, Nishio K, Saijo N Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008, 99:1757-1762.
17. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
18. AJCC Cancer Staging Manual, 6th edn. Ann Oncol 2003, 14:345-346.
19. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
20. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
21. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994, 30A:635-642. EORTC Study Group on Quality of Life.
22. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran C, Bottomley A EORTC QLQ-C30 Scoring Manual, third edn. (accessed July 1, 2013). http://www.eortc.be/qol/files/SCManualQLQ-C30.pdf.
23. Osoba D, Rodrigues G, Myles J, Zee B, Pater J Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16:139-144.
24. Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase iii study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3342-3350.
25. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
26. Yang JC, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013, 13:729-736.
27. Lacouture ME, Schadendorf D, Chu CY, et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 2013, 13:721-728.
28. Horiike A, Nishio M, Goto K, et al. A phase II study of erlotinib as first-line treatment in Japanese advanced NSCLC patients harboring EGFR mutations. Ann Oncol 2012, 23:IX413.
29. Douillard J, Ostoros G, Cobo M, et al. Efficacy, safety and tolerability results from a phase IV, open-label, single arm study of 1st-line gefitinib in Caucasian patients (PTS) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer 2013, 80:S31.